AI-powered lung cancer screening

Find patients.
Diagnose smarter.
Save lives.

Lung cancer screening saves lives, but most eligible patients are never identified. We use AI to estimate pack-year smoking history from your EHR, find who qualifies, and give radiologists a second CADx diagnostic opinion on every LDCT scan

For FQHCs For Hospitals
LungIQ LungAI
Scanning EHR Records
JM
James Martinez
Age 58 | No smoking hx
Not eligible
RK
Rachel Kim
Age 44 | 8 pack-yr
Not eligible
TS
Thomas Sullivan
Age 62 | 20 pack-yr | Former smoker
Eligible
AL
Amy Lin
Age 39 | No smoking hx
Not eligible
DW
David Washington
Age 67 | 35 pack-yr | Current smoker
Eligible
3,600 eligible of 35,000 patients identified
LDCT scan with LungAI nodule detection
Nodule Detected
11.2 mm, 352.4 mm3
LungAI Score: 0.3 (low risk)
Outcome: Confirmed benign
Simulated CADe viewer. LungAI provides the malignancy risk score only. Viewer software provided by imaging center CADe partners.
LungAI is an investigational medical device and has not been cleared by FDA. Oatmeal Health is preparing a 510(k) premarket notification for submission to FDA. LungAI is not commercially available in the United States. Clinical performance data reflect retrospective studies on held-out datasets; results may differ in prospective use.
131,880
Americans die from lung cancer every year.

More than breast, colon, and prostate cancers combined. Most are found too late because the system never looked.

~80%

Diagnosed at late stage, when 5-year survival drops under 9%

64.7%

Survival rate when caught early at Stage I or II

14-20M+

Americans eligible for free annual LDCT screening

<6%

Screened in underserved FQHC communities, where the gap is widest

Sources: ACS Cancer Facts 2024, USPSTF 2021, NLST, NCI SEER

Trusted Partners
Cedars-Sinai Camarena Health Fox Chase Cancer Center Stanford Health Care Mount Sinai Health System Partner Partner
How It Works

One platform. Three partners.
Every patient found.

Lung cancer screening fails because the system is fragmented. FQHCs have the patients. Hospitals have the scanners. Payers have the incentive. We connect all three.

Doctor consulting with patient at community health center
Community Health Centers
Find the patients no one else finds
FQHCs serve 34M+ lives, many with the highest smoking prevalence and lowest screening rates. LungIQ scans EHR data to identify eligible patients, even when smoking history was never entered into structured fields.
  • LungIQ 0.96 AUROC patient identification
  • 9x faster than manual chart review
  • Eligible patients referred to partner imaging centers
  • Reimbursable shared decision-making visits (G0296)
Find hidden patients
Radiologist reviewing CT lung scan
Hospitals & Imaging Centers
Screen more patients. Diagnose with confidence.
Hospitals receive a steady referral pipeline from FQHC partners. Post-FDA clearance, LungAI adds a reimbursable AI diagnostic layer inside the radiologist's existing viewer. No new workstation. No new login.
  • LungIQ Identify eligible patients in-system too
  • LungAI Malignancy scoring 0 to 100, per nodule
  • New revenue via CPT 0721T (post-FDA clearance)
  • Fewer missed cancers. Fewer unnecessary biopsies.
Review the evidence
*Pre-FDA 510(k) clearance. NLST held-out retrospective study. Results may differ in prospective clinical use.
Healthcare data analytics dashboard
Health Plans
Turn screening spend into measurable savings
LDCT screening is already an ACA-mandated benefit. Payers are paying for it. The question is what they're getting from it. Earlier detection shifts costs from $200K+ per patient (Stage IV) to $54K (Stage I).
  • No new coverage policy or billing model required
  • 4 to 6x ROI from early detection vs late-stage treatment
  • HEDIS lung screening measure expected (NCQA)
  • Claims-validated PMPM model, built with your actuaries
Partner with us
Jonathan Govette, CEO and Co-Founder of Oatmeal Health
Our Story
A mission born from personal loss
After losing more than ten family members to cancer, Jonathan Govette founded Oatmeal Health to make sure fewer families have to endure the same. We built the platform we wish had existed.
Read our story →
“
We can defuse the cancer time bomb, but only if we find people earlier.
Jonathan Govette CEO and Co-Founder

Ready to close the lung cancer screening gap?

Whether you are an FQHC, health system, or health plan, we have a program built for you.

Get started